Autoimmune Profile Updates
Test in Focus
Mayo Clinic Laboratories is adjusting a number of its autoimmune profiles by removing certain antibodies from those profiles. In this "Test in Focus" episode of the "Answers From the Lab" podcast, Andrew McKeon, M.B., B.Ch., M.D., explains the rationale behind the test updates.
"These are not radical changes by any means. This is something that's been evolving over time," Dr. McKeon says. "We've collected data to drill down on the significance of test results in different phenotypes. Based on that, we're recalibrating our profiles to make sure what's in there is of the highest clinical utility for our providers." Listen to learn more from Dr. McKeon about the specifics of the autoimmune profile updates, and how the changes will streamline testing and enhance test interpretation.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
The latest from Test in Focus
Divyanshu (Div) Dubey, M.B.B.S., explains how Mayo Clinic Labs’ new Kelch-11 antibody test — the first in the world — can confirm diagnosis, guide treatment, and improve outcomes in patients affected by testicular cancer-associated paraneoplastic encephalitis.
Sanjeev Sethi, M.D., Ph.D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic certainty and insight on disease expression.